WO2005115421A8 - Use of a compound comprising d-mannoheptulose and/or perseitol for treating and preventing innate immunity modification diseases - Google Patents

Use of a compound comprising d-mannoheptulose and/or perseitol for treating and preventing innate immunity modification diseases

Info

Publication number
WO2005115421A8
WO2005115421A8 PCT/FR2005/001075 FR2005001075W WO2005115421A8 WO 2005115421 A8 WO2005115421 A8 WO 2005115421A8 FR 2005001075 W FR2005001075 W FR 2005001075W WO 2005115421 A8 WO2005115421 A8 WO 2005115421A8
Authority
WO
WIPO (PCT)
Prior art keywords
compound
perseitol
mannoheptulose
treating
preventing
Prior art date
Application number
PCT/FR2005/001075
Other languages
French (fr)
Other versions
WO2005115421A1 (en
Inventor
Antoine Piccirilli
Nathalie Piccardi
Philippe Msika
Francois Paul
Stephanie Bredif
Original Assignee
Expanscience Lab
Antoine Piccirilli
Nathalie Piccardi
Philippe Msika
Francois Paul
Stephanie Bredif
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Expanscience Lab, Antoine Piccirilli, Nathalie Piccardi, Philippe Msika, Francois Paul, Stephanie Bredif filed Critical Expanscience Lab
Priority to CN2005800200168A priority Critical patent/CN1968707B/en
Priority to US11/587,961 priority patent/US7897579B2/en
Priority to EP05763732.4A priority patent/EP1763355B1/en
Priority to ES05763732T priority patent/ES2769246T3/en
Priority to MXPA06012556A priority patent/MXPA06012556A/en
Priority to JP2007510081A priority patent/JP4903131B2/en
Publication of WO2005115421A1 publication Critical patent/WO2005115421A1/en
Publication of WO2005115421A8 publication Critical patent/WO2005115421A8/en
Priority to US12/929,684 priority patent/US9023810B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant

Abstract

The invention relates to the use of a compound comprising D-mannoheptulose and/ or perseitol for producing a drug for treating and/or preventing diseases related to the modification of an innate and/or acquired immunity by increasing the production of antimicrobial peptides, preferably hBD-2 without inducing inflammatory reactions, irritation or intolerance. Said compound can also comprise a peptidic avocado extract an/or a peptidic lupin extract.
PCT/FR2005/001075 2004-04-30 2005-04-29 Use of a compound comprising d-mannoheptulose and/or perseitol for treating and preventing innate immunity modification diseases WO2005115421A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CN2005800200168A CN1968707B (en) 2004-04-30 2005-04-29 Use of a compound comprising D-mannoheptulose and/or perseitol for treating and preventing innate immunity modification diseases
US11/587,961 US7897579B2 (en) 2004-04-30 2005-04-29 Use of a compound comprising D-mannoheptulose and/or perseitol for treating and preventing innate immunity modification diseases
EP05763732.4A EP1763355B1 (en) 2004-04-30 2005-04-29 Composition comprising D-mannoheptulose and/or perseitol for the treatment or prevention of diseases linked to a modification of the innate and/or acquired immunity
ES05763732T ES2769246T3 (en) 2004-04-30 2005-04-29 Composition comprising D-mannoheptulose and / or perseitol for the treatment or prevention of diseases related to a modification of innate and / or acquired immunity
MXPA06012556A MXPA06012556A (en) 2004-04-30 2005-04-29 Use of a compound comprising d-mannoheptulose and/or perseitol for treating and preventing innate immunity modification diseases.
JP2007510081A JP4903131B2 (en) 2004-04-30 2005-04-29 Use of a compound comprising D-mannoheptulose and / or perseitol for the treatment and prevention of innate immune modulatory diseases
US12/929,684 US9023810B2 (en) 2004-04-30 2011-02-08 Use of a compound comprising D-mannoheptulose and/or perseitol for treating and preventing innate immunity modification diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0404635 2004-04-30
FR0404635A FR2869541B1 (en) 2004-04-30 2004-04-30 USE OF A COMPOSITION COMPRISING D-MANNOHEPTULOSE AND / OR PERSEITOL FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH A CHANGE IN INITIATED IMMUNITY

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/587,961 A-371-Of-International US7897579B2 (en) 2004-04-30 2005-04-29 Use of a compound comprising D-mannoheptulose and/or perseitol for treating and preventing innate immunity modification diseases
US12/929,684 Division US9023810B2 (en) 2004-04-30 2011-02-08 Use of a compound comprising D-mannoheptulose and/or perseitol for treating and preventing innate immunity modification diseases

Publications (2)

Publication Number Publication Date
WO2005115421A1 WO2005115421A1 (en) 2005-12-08
WO2005115421A8 true WO2005115421A8 (en) 2006-02-16

Family

ID=34944685

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2005/001075 WO2005115421A1 (en) 2004-04-30 2005-04-29 Use of a compound comprising d-mannoheptulose and/or perseitol for treating and preventing innate immunity modification diseases

Country Status (8)

Country Link
US (2) US7897579B2 (en)
EP (1) EP1763355B1 (en)
JP (1) JP4903131B2 (en)
CN (1) CN1968707B (en)
ES (1) ES2769246T3 (en)
FR (1) FR2869541B1 (en)
MX (1) MXPA06012556A (en)
WO (1) WO2005115421A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9415083B2 (en) 2004-05-10 2016-08-16 Mars, Incorporated Method for decreasing inflammation and stress in a mammal

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563522B2 (en) * 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US7666459B2 (en) * 2001-09-12 2010-02-23 The Procter & Gamble Company Pet food compositions
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US9089576B2 (en) 2004-04-30 2015-07-28 Laboratoires Expanscience Medicament comprising a peptide extract of avocado, which is intended for the treatment and prevention of illnesses that are linked to an immune system deficiency or oxidative stress or skin ageing or dry skin
US20090252834A1 (en) * 2004-05-10 2009-10-08 Michael Griffin Hayek Compositions comprising glucose anti-metabolites
US20050249837A1 (en) * 2004-05-10 2005-11-10 The Procter & Gamble Company Processes for preparing plant matter extracts and pet food compositions
EP1880001B1 (en) 2005-05-31 2011-06-08 The Iams Company Feline probiotic lactobacilli
ES2607988T3 (en) 2005-05-31 2017-04-05 Iams Europe B.V. Feline probiotic bifidobacteria
FR2905270B1 (en) * 2006-08-31 2010-03-26 Expanscience Lab USE OF C7 SUGARS IN THE PREVENTION AND TREATMENT OF MYCOSES
FR2910815B1 (en) 2006-12-28 2010-10-29 Expanscience Lab COMPOSITION COMPRISING AN EXTRACT OF QUINOA SEEDS
CA2675510A1 (en) * 2007-02-01 2008-08-07 The Iams Company Method for decreasing inflammation and oxidative stress in mammals
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
FR2938193B1 (en) * 2008-11-07 2011-08-12 Expanscience Lab MEDICAMENT OR DERMATOLOGICAL COMPOSITION COMPRISING A PEPTIDE AVOCADO EXTRACT FOR THE TREATMENT AND PREVENTION OF PRUPIT
FR2940112B1 (en) * 2008-12-22 2011-03-25 Rocher Yves Biolog Vegetale PROCESS FOR EXTRACTING COMPOUNDS PRESENT WITHIN A FRESH VEGETABLE MATERIAL BY CRYOBROYING AND ENZYMOLYSIS
JP2010180141A (en) * 2009-02-03 2010-08-19 Nisshin Pharma Inc Anti-allergic composition
FR2945943B1 (en) * 2009-06-01 2015-04-03 Lvmh Rech USE OF A VEGETABLE EXTRACT RICH IN POLYPHENOLS AS ANTIOXIDANT AGENT IN ASSOCIATION WITH A HYDRATING OR HUMICIZING AGENT
FR2948566B1 (en) 2009-07-30 2012-08-10 Expanscience Lab EXTRACT OF SCHIZANDRA SPHENANTHERA FRUIT AND COSMETIC, DERMATOLOGICAL AND NUTRACEUTICAL COMPOSITIONS COMPRISING SAME
FR2948565B1 (en) 2009-07-30 2011-10-28 Expanscience Lab COSMETIC COMPOSITION FOR THE TREATMENT OF ACNE COMPRISING A PETIDIC EXTRACT FROM SCHIZANDRA
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
FR2953135B1 (en) * 2009-11-30 2012-05-11 Expanscience Lab MACROSTACHYA ACACIA SEED EXTRACT AND COSMETIC, PHARMACEUTICAL, DERMATOLOGICAL, NUTRACEUTICAL OR FOOD COMPOSITIONS COMPRISING THE SAME
FR2953136B1 (en) 2009-11-30 2012-05-11 Expanscience Lab EXTRACT OF VIGNA UNGUICULATA SEEDS AND COSMETIC, PHARMACEUTICAL, DERMATOLOGICAL, NUTRACEUTICAL OR FOOD COMPOSITIONS COMPRISING THE SAME
FR2953722B1 (en) 2009-12-16 2012-03-09 Expanscience Lab COMPOSITION COMPRISING AT LEAST ONE C7 SUGAR FOR THE TREATMENT OF ALOPECIA, FOR THE COSMETIC TREATMENT OF PHANES, AND FOR THE CARE OF HAIR, CILES OR NAILS
US20120115798A1 (en) * 2010-11-04 2012-05-10 Stefan Patrick Massimino Method for improving the immunity of a companion animal
FR2969495B1 (en) 2010-12-22 2013-10-11 Expanscience Lab EXTRACT OF MACA-RICH AERIAL PARTS OF POLYPHENOLS AND COMPOSITION COMPRISING THE SAME
FR2969496B1 (en) * 2010-12-22 2013-11-08 Expanscience Lab EXTRACT OF PULP AND / OR AVOCADO SKIN RICH IN POLYPHENOLS AND COSMETIC, DERMATOLOGICAL AND NUTRACEUTICAL COMPOSITIONS COMPRISING SAME
FR2975004B1 (en) 2011-05-13 2013-06-28 Expanscience Lab NEW ANTI-REDNESS ACTIVE INGREDIENTS AND COSMETIC COMPOSITIONS COMPRISING THE SAME
FR2993282B1 (en) 2012-07-13 2017-11-10 Expanscience Lab METHOD FOR IDENTIFYING MOLECULAR MARKERS OF CHILD'S SKIN
FR2999429B1 (en) 2012-12-18 2015-01-02 Expanscience Lab EXTRACT OF PASSIFLORE SEEDS AND COSMETIC, PHARMACEUTICAL, DERMATOLOGICAL OR NUTRACEUTICAL COMPOSITIONS COMPRISING SAME
JP6017953B2 (en) * 2012-12-28 2016-11-02 花王株式会社 Skin external composition
FR3001889B1 (en) * 2013-02-11 2021-02-12 Expanscience Lab USE OF A COMPOSITION CONTAINING AVOCADO PERSEOSE IN THE PROTECTION OF EPIDERMAL STEM CELLS.
EP2781218A1 (en) * 2013-03-21 2014-09-24 Medizinische Universität Wien Use of sedoheptulose as a nutritional supplement
FR3010906B1 (en) 2013-09-25 2016-12-23 Expanscience Lab LIPID EXTRACT OF PASSIFLOWER SEEDS
CA2929933A1 (en) * 2013-11-11 2015-05-14 The Iams Company Processes for preparing a carbohydrate extract comprising mannoheptulose and compositions comprising same
FR3016373B1 (en) 2014-01-10 2018-01-19 Laboratoires Expanscience MAMMELON SKIN MODEL RECONSTITUTES
FR3028764B1 (en) 2014-11-26 2016-12-09 Expanscience Lab PEPTIDE AND OSIDIC FRUIT EXTRACT OF SCHIZANDRA AND IMPROVEMENT OF THE NEUROSENSORY SKIN SYSTEM RESPONSE
CN105439814A (en) * 2015-12-09 2016-03-30 广西壮族自治区中国科学院广西植物研究所 Method for preparing D-mannoheptulose and persitol by extraction from avocado
FR3045669B1 (en) 2015-12-16 2019-04-05 Laboratoires Expanscience METHODS OF EVALUATING THE EFFECTS OF DEHYDRATION ON CHILDREN'S SKIN
WO2018031286A1 (en) * 2016-08-08 2018-02-15 Yale University Compositions and methods of treatment using glucose analogs
FR3098405B1 (en) 2019-07-12 2021-06-25 Expanscience Lab Composition comprising passionflower seed polyphenols, avocado peptides and witch hazel extract and use to treat and / or prevent stretch marks
CN113262234B (en) * 2021-06-11 2022-04-26 河南大学 Application of monosaccharide derivative in preparation of immunoregulation medicine

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722843A (en) * 1985-01-07 1988-02-02 Vinson William L Moisturizing nutritive and healing skin cream
JPH01132517A (en) * 1987-11-18 1989-05-25 Toyama Chem Co Ltd Antibiotic composition
JPH0291024A (en) * 1988-09-28 1990-03-30 Nippon Oil & Fats Co Ltd Physiologically active lipid
JP3577721B2 (en) * 1993-07-14 2004-10-13 三省製薬株式会社 External preparation for skin
GB9315846D0 (en) 1993-07-30 1993-09-15 Isis Innovation Tumour inhibitors
JP3669395B2 (en) * 1996-11-01 2005-07-06 株式会社ノエビア Powder composition
FR2762512B1 (en) 1997-04-24 2000-10-13 Pharmascience Lab LUPINE OIL COMPOSITIONS, ESPECIALLY BASED ON LUPINE OIL AND WHEAT GERM OIL AND THEIR USE IN COSMETOLOGY, PHARMACY AND AS A FOOD SUPPLEMENT
US20020035071A1 (en) * 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
JP2000159646A (en) * 1998-11-26 2000-06-13 Lion Corp Polyvinyl alcohol hydrogel composition for mouth
FR2792202B1 (en) * 1999-04-19 2003-06-13 Pharmascience Lab LUPINE PEPTIDE EXTRACT AND PHARMACEUTICAL OR COSMETIC OR NUTRACEUTICAL COMPOSITION COMPRISING SUCH EXTRACT
JP4143223B2 (en) * 1999-07-30 2008-09-03 一丸ファルコス株式会社 Cosmetic composition containing moisturizing plant extract
FR2798591B1 (en) 1999-09-22 2001-10-26 Pharmascience Lab USE OF A VEGETABLE OIL PRODUCT FOR INCREASING THE SYNTHESIS OF SKIN LIPIDS IN COSMETICS, PHARMACY OR DERMATOLOGY AND AS A FOOD ADDITIVE
AU768306B2 (en) * 1999-10-14 2003-12-04 Nisshin Oil Mills, Ltd., The Skin-care agents, skin antiaging agents, whitening agents and external skin preparations
US6861077B1 (en) * 2000-03-17 2005-03-01 L'oreal S.A. Use of plant extracts in a cosmetic composition to protect keratinous fibers
GB2361641B8 (en) * 2000-04-28 2012-04-04 Lush Ltd Cosmetic lotions.
JP4589483B2 (en) * 2000-05-12 2010-12-01 花王株式会社 Acne preventive and therapeutic agent
US6896914B2 (en) * 2001-10-26 2005-05-24 David I. Chapnick Method for normalizing insulin levels
JP2004016057A (en) * 2002-06-14 2004-01-22 Ogawa & Co Ltd Flavor deterioration inhibitor
US6733795B2 (en) * 2002-07-30 2004-05-11 Laboratoires Expanscience Method for producing an avocado leaf extract rich in furanic lipids
FR2843027B1 (en) 2002-07-30 2005-12-30 Expanscience Lab PROCESS FOR OBTAINING AN EXTRACT OF AVOCADO LEAVES RICH IN FURNA LIPIDS
EP1526861B1 (en) 2002-07-30 2007-11-21 Laboratoires Expanscience Method for producing avocado leaves extract rich in furan lipids
FR2843125B1 (en) * 2002-08-02 2012-11-16 Coletica ACTIVE PRINCIPLES STIMULATING HUMAN BETA-DEFENSIVE TYPE 2 AND / OR TYPE 3, AND COSMETIC OR PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH ACTIVE INGREDIENTS
FR2869543B1 (en) * 2004-04-30 2006-07-28 Expanscience Laboratoires Sa MEDICAMENT COMPRISING A PEPTIDE AVOCADO EXTRACT FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH A DEFICIENCY OF THE IMMUNE SYSTEM

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9415083B2 (en) 2004-05-10 2016-08-16 Mars, Incorporated Method for decreasing inflammation and stress in a mammal

Also Published As

Publication number Publication date
US7897579B2 (en) 2011-03-01
JP4903131B2 (en) 2012-03-28
CN1968707B (en) 2013-05-29
JP2007535523A (en) 2007-12-06
ES2769246T3 (en) 2020-06-25
US9023810B2 (en) 2015-05-05
MXPA06012556A (en) 2007-01-31
US20080113921A1 (en) 2008-05-15
FR2869541A1 (en) 2005-11-04
EP1763355B1 (en) 2019-11-06
FR2869541B1 (en) 2007-12-28
US20110274778A1 (en) 2011-11-10
CN1968707A (en) 2007-05-23
WO2005115421A1 (en) 2005-12-08
EP1763355A1 (en) 2007-03-21

Similar Documents

Publication Publication Date Title
WO2005115421A8 (en) Use of a compound comprising d-mannoheptulose and/or perseitol for treating and preventing innate immunity modification diseases
WO2006095029A3 (en) Di-polymer protein conjugates and processes for their preparation
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
ZA200703601B (en) Medicaments for the treatment or prevention of fibriotic diseases
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
CY1108514T1 (en) 1-PHENYLCANECARVOXYLIC ACID DERIVATIVE FOR TREATMENT OF NEUROLOGICAL DISEASES
WO2005063201A3 (en) Liposomes and liposomal compositions for vaccination and drug delivery
WO2006058868A3 (en) Substituted pteridines for treating inflammatory diseases
WO2002094228A8 (en) Prevention and treatment of allergies by helminthic regulation of ige
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
WO2004071382A3 (en) Substituted heterocycles
WO2007135026A3 (en) Substituted pteridines as therapeutic agents
PT1835907E (en) Medicaments for the treatment or prevention of fibrotic diseases
HK1104460A1 (en) Use for the manufacture of a medicament for treatment or prophylaxis of infectious diseases
WO2008067982A3 (en) Use of carrageenan for treating rhinovirus infections
WO2007051785A3 (en) Use of sdf-1 for the treatment and/or prevention of neurological diseases
WO2007056301A3 (en) Antibody therapy for treatment of diseases associated with gluten intolerance
WO2003039539A3 (en) Use of endothelin receptor antagonists in the treatment of tumour diseases
WO2002087596A3 (en) Use of azithromycin for the manufacture of a medicament for treatment of non-infective inflammatory diseases
WO2007009686A3 (en) Substituted pyrazoline compounds, their preparation and use as medicaments
WO2005092062A3 (en) Compounds for neurodegenerative disorders
WO2008043788A3 (en) Novel compounds
WO2006016219A3 (en) Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
WO2008039409A3 (en) Methods and kits for use in the treatment and prevention of diseases or conditions of the immune system or infectious diseases
EP1741430A4 (en) Remedy for psychoneurotic diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE

WWE Wipo information: entry into national phase

Ref document number: 11587961

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/012556

Country of ref document: MX

Ref document number: 2007510081

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005763732

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200580020016.8

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005763732

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11587961

Country of ref document: US